The user has been using finasteride every other day and oral minoxidil for hair regrowth, noticing new baby hairs. They are hopeful about regaining hair on their temples.
The user shared their positive experience with hair regrowth using oral finasteride and minoxidil, noting significant progress after nine months despite initial doubts and side effects. They emphasized the importance of patience, consistent treatment, and lifestyle changes like reducing stress and improving health.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.
A 30-year-old shared positive results after 6 months of using 1mg oral finasteride daily for hair loss, without minoxidil. Hair loss stopped around month 2, and noticeable regrowth began around month 4.5, with no side effects reported.
A user is concerned about the long-term commitment and potential side effects of using oral finasteride and topical minoxidil for hair loss. They are debating whether to accept their hair loss or start the treatment despite mixed results from others.
Minoxidil is harmful to pets, especially cats, if they contact it. Users recommend switching to oral minoxidil or taking precautions like washing hands and using head coverings to prevent exposure.
Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.
The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.